Prosecution Insights
Last updated: April 19, 2026

DANA-FARBER CANCER INSTITUTE, INC.

5 pending office actions • 3 clients

Portfolio Summary

5
Total Pending OAs
0
Final Rejections
5
Non-Final OAs

Client Portfolio (3 clients)

Client (Assignee)Pending OAs
DANA-FARBER CANCER INSTITUTE, INC. 2
DANA-FARBER CANCER INSTITUTE, INC. 2
Dina Stroopinsky 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18289568 ANTIBODIES AGAINST ALK AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. WEIDNER, ADAM M 1675 Non-Final OA Nov 05, 2023
18554429 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER Dina Stroopinsky PIHONAK, SARAH 1627 Non-Final OA Oct 10, 2023
18285413 BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS DANA-FARBER CANCER INSTITUTE, INC. DONOHUE, SEAN R 1618 Non-Final OA Oct 03, 2023
18283264 ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS DANA-FARBER CANCER INSTITUTE, INC. BURKETT, DANIEL JOHN 1624 Non-Final OA Sep 21, 2023
18031257 GERMLINE BIOMARKERS OF CLINICAL RESPONSE AND BENEFIT TO IMMUNE CHECKPOINT INHIBITOR THERAPY DANA-FARBER CANCER INSTITUTE, INC. HINES, JANA A 1645 Non-Final OA Apr 11, 2023

Managing DANA-FARBER CANCER INSTITUTE, INC.'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month